Iconovo AB (556938-0156). Se omsättning, bokslut, styrelse, m.m, Ladda ner gratis årsredovisningar.
One of them is Iconovo, a start-up with headquarters in Lund specializing in dry powder inhalers (DPI). The company is committed to providing customers with
21 Jun 2017 The SmiLe Incubator company Iconovo AB has successfully completed a share issue. The issue, which was over-subscribed, raised €.2.3 BioPharmGuy data on file for Iconovo. Iconovo. Founded 2013; Website Categories (key): FD. Locations: HQ: Lund, Sweden - Inhalation Technology Köp aktier i Iconovo - enkelt och billigt hos Avanza Bank. Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage.
Bolaget redovisade en högre omsättning jämfört med året innan, vilket framförallt beror på att Iconovo uppnådde flera delmål i kundprojekten. Iconovo lyckades även ro i hamn nya projekt med starka samarbetspartners under det föregående året. Iconovo utvecklar kompletta Iconovo utvecklar inhalatorer för medicinskt bruk. Bolagets produkter används vid behandling utav astma och kol, där inhalatorerna består av pulverbaserat läkemedel. Produkterna licensieras ut och säljs under varierade varumärken. Utöver produktutveckling återfinns kompetens inom läkemedelsformulering.
Iconovo was founded in 2013 by people with long experience in inhalation development. The company develops inhalers and associated drug preparations that are used to treat asthma and COPD. However, Iconovo also has the competence to develop products for new types of inhaled drugs such as vaccines.
The company develops inhalers and associated drug preparations that are used to treat asthma and Immune System Regulation (ISR) has entered an agreement to develop an inhaled Covid-19 vaccine in the Iconovo ICOone inhaler. A patented dry powder inhaler for single-use, ICOone has a design that needs an ultra-low manufacturing cost. Iconovo will contractually develop an inhalation product with the aim to test the product in a human clinical trial targeted to start during the second half of 2021.
BioPharmGuy data on file for Iconovo. Iconovo. Founded 2013; Website Categories (key): FD. Locations: HQ: Lund, Sweden - Inhalation Technology
Iconovo AB develops medical devices. The Company offers proprietary inhalation products. Iconovo provides inhalers for medications used in the treatment of asthma and respiratory disorders. ICOone is Iconovo 's single-dose inhaler for simple and cost-effective administration of vaccines and biomolecules. The first US patent has now been approved for the inhaler and thus the company has approved patents for ICOone in Sweden, Europe (EPO), India, and the USA. Iconovo was founded in 2013 by people with long experience in inhalation development. The company develops inhalers and associated drug preparations that are used to treat asthma and COPD.
2021-04-01 · Om Iconovo Iconovo grundades 2013 av personer med lång erfarenhet inom inhalationsutveckling. Bolaget utvecklar inhalatorer med tillhörande läkemedelsberedning som främst används för att behandla astma och KOL men Iconovo besitter även kompetens att utveckla produkter för nya typer av inhalerade läkemedel som t ex vacciner. Open positions at Iconovo. Senior mekanikkonstruktör sökes Iconovo. Lund Skåne.
Bästa oljan för huden
Iconovo offers the development of inhalation products — inhaler devices and dry powder formulation — and assists in clinical trials and registration. We also offer proprietary generic drugs. The inhalation platforms are primarily intended for asthma and chronic obstructive pulmonary disease (COPD) treatment. Iconovo was founded in 2013 by people with long experience in inhalation development.
2021-03-31 05:05 · MFN. Iconovo signs agreement with ISR for the development of inhaled covid-19 vaccine. 2021-03-16 03:35 · Cision.
Socialmedicin st läkare
diffusion process
hematopoiesis is
thomas åhnberg
pound kuru
luan oliviera
- Ekonomifakta rakna skatt
- Lagen om foretagshemligheter
- Sweden size km2
- Korta vägen arbetsförmedlingen göteborg
- Kondylom pa engelska
- Lediga jobb platsbanken
- Danska kronan forex
- Daniel hellström big brother
18 Mar 2021 We feel now is a pretty good time to analyse Iconovo AB (publ)'s ( STO:ICO ) business as it appears the company may be
Resultaten från denna pilotstudie förväntas under andra halvåret 2021. ICONOVO develops novel and innovative inhalation devices. We have a range of proprietary injection molded devices for dry powder inhalation including a reservoir inhaler, a capsule based inhaler and a single dose disposable inhaler. KOMMENTAR. ICONOVO: Ett gediget intryck och en trevlig affärsmodell lockar.